The Library
Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy - the national cancer centre Singapore experience
Tools
Tham, Ivan Weng-Keong, Hee, Siew Wan, Yeo, Richard Ming-Chert, Salleh, Patemah Bte, Lee, James, Tan, Terence Wee-Kiat, Fong, Kam Weng, Chua, Eu Tiong and Wee, Joseph Tien-Seng (2009) Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy - the national cancer centre Singapore experience. International Journal of Radiation Oncology*Biology*Physics, 75 (5). pp. 1481-1486. doi:10.1016/j.ijrobp.2009.01.018 ISSN 0360-3016.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1016/j.ijrobp.2009.01.018
Abstract
Purpose:
The aim of this study was to determine the efficacy and acute toxicity of our early experience with treating nasopharyngeal carcinoma (NPC) patients with intensity-modulated radiotherapy (IMRT).
Methods and materials:
A review was conducted on case records of 195 patients with histologically proven, nonmetastatic NPC treated with IMRT between 2002 and 2005. MRI of the head and neck was fused with CT simulation images. All plans had target volumes at three dose levels, with a prescribed dose of 70 Gy to the gross disease, in 2.0–2.12 Gy/fraction over 33–35 fractions. Cisplatin-based chemotherapy was offered to Stage III/IV patients.
Results:
Median patient age was 52 years, and 69% were male. Median follow-up was 36.5 months. One hundred and twenty-three patients had Stage III/IV disease (63%); 50 (26%) had T4 disease. One hundred and eighty-eight (96%) had complete response; 7 (4%) had partial response. Of the complete responders, 10 (5.3%) had local recurrence, giving a 3-year local recurrence-free survival estimate of 93.1% and a 3-year disease-free survival of 82.1%. Fifty-one patients (26%) had at least one Grade 3 toxicity.
Conclusions:
Results from our series are comparable to those reported by other centers. Acute toxicity is common. Local failure or persistent disease, especially in patients with bulky T4 disease, are issues that must be addressed in future trials.
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Statistics and Epidemiology Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
Journal or Publication Title: | International Journal of Radiation Oncology*Biology*Physics | ||||
Publisher: | Elsevier | ||||
ISSN: | 0360-3016 | ||||
Official Date: | 1 December 2009 | ||||
Dates: |
|
||||
Volume: | 75 | ||||
Number: | 5 | ||||
Page Range: | pp. 1481-1486 | ||||
DOI: | 10.1016/j.ijrobp.2009.01.018 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |